Sentien Reports on Data from First Ph I/II Study of SBI-101 in Subjects with AKI in STEM CELLS Translational Medicine
Filter: PRESS RELEASES IN THE NEWS EVENTS
Sentien Reports on Data from First Ph I/II Study of SBI-101 in Subjects with AKI in STEM CELLS Translational Medicine
Scientists are reporting promising results in the early stages of a clinical trial designed to gauge the feasibility of a new type of treatment for people with acute kidney disease. Released in STEM CELLS Translational Medicine, the study shows how mesenchymal stromal cells (MSCs) delivered using a new ex vivo drug delivery system – SBI-101 – can keep MSCs viable longer and reprogram the peripheral immune response toward organ repair.
